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Cardiac insulin resistance is a metabolic and functional disorder that is often associated with obesity and/or the cardiorenal
metabolic syndrome (CRS), and this disorder may be accentuated by chronic alcohol consumption. In conditions of over-
nutrition, increased insulin (INS) and angiotensin II (Ang II) activate mammalian target for rapamycin (mTOR)/p70 S6 kinase
(S6K1) signaling, whereas chronic alcohol consumption inhibits mTOR/S6K1 activation in cardiac tissue. Although excessive
activation of mTOR/S6K1 induces cardiac INS resistance via serine phosphorylation of INS receptor substrates (IRS-1/2), it also
renders cardioprotection via increased Ang II receptor 2 (AT2R) upregulation and adaptive hypertrophy. In the INS-resistant and
hyperinsulinemic Zucker obese (ZO) rat, a rodent model for CRS, activation of mTOR/S6K1signaling in cardiac tissue is regulated
by protective feed-back mechanisms involving mTOR↔AT2R signaling loop and proﬁle changes of microRNA that target S6K1.
Such regulation may play a role in attenuating progressive heart failure. Conversely, alcohol-mediated inhibition of mTOR/S6K1,
down-regulation of INS receptor and growth-inhibitory mir-200 family, and upregulation of mir-212 that promotes fetal gene
program may exacerbate CRS-related cardiomyopathy.
1.Introduction
The conﬂuence of a constellation of interactive maladap-
tive factors such as hypertension, insulin (INS) resistance,
metabolic dyslipidemia, obesity, microalbuminuria, and/or
reduced renal function constitute the cardiorenal metabolic
syndrome(CRS)[1–6].Clusteringtheincreasingnumbersof
these risk factors within an individual heightens metabolic
perturbations which, in turn, promote development of
cardiovascular diseases (CVD) and type 2 diabetes (T2DM)
[5, 6]. The CRS aﬀects more than one-third of the US pop-
ulation and is rising to pandemic proportions worldwide.
Overnutrition caused by excessive consumption of diets
rich in carbohydrates, largely from highly processed foods
and sugar-sweetened beverages (Western diet), positively
correlates with the rise of CRS risk factors and CVD [7–14].
Overnutrition results in chronic exposure of cardiovascular
(CV) tissues to circulating nutrients, glucose, and INS.
All of these factors promote attenuation of INS metabolic
signaling and INS resistance independently, and therefore,
collectively they exert signiﬁcant stress on CV tissues [15–
19]. Moreover, overnutrition induces activation of the renin-
angiotensin system (RAS) which can elevate systemic and
tissue angiotensin II (Ang II), a potent vasoconstrictive and
proinﬂammatory hormone. Ang II-mediated activation of
Ang II type 1 receptor (AT1R) promotes both INS resistance
and CVD, and inhibition of Ang II generation, as well as
blocking of AT1R signaling, has proven to be beneﬁcial
in treatment of INS resistance [20–32]. Overnutrition also
alters adipocyte functions by reducing secretion of anti-
inﬂammatory, anti-ischemic adiponectin and increasing
secretion of proinﬂammatory, prothrombotic adipokines
suchasresistin[33–35].Thus,inconditionsofovernutrition,
cardiac insult is exerted by a plethora of extracellular2 Experimental Diabetes Research
signals (increased INS and Ang II, an adverse adipokine
proﬁle, and excessive glucose, amino acids and lipids)
andhemodynamic/neuroendocrinestressesoriginatingfrom
hypertension, hypertrophy, and ﬁbrosis.
In the initial stages of overnutrition related cardiac
INS resistance, several compensatory mechanisms are
activated in heart tissue to protect the functions of this vital
organ by promoting adaptive compensatory signaling and
remodeling. In this context, activation of the nutrient sensor
kinase mammalian target for rapamycin (mTOR) in cardiac
tissue, under conditions of overnutrition, is particularly
noteworthy [36]. The mTOR Complex 1 (mTORC1) serves
asaconvergingpointforsignalsfromnutrients,INSandAng
II, and is frequently activated in CV tissues in conditions of
overnutritionandaging[36–44].Ontheonehand,increased
mTORC1-mediated signaling is implicated in left ventricular
(LV) remodeling, myocardial infarction, hypertrophic
cardiomyopathy, and atherosclerosis [45–48]. Conversely,
mTORisrequiredforexercise-inducedadaptivehypertrophy
and remodeling [49]. Attenuation of mTORC1 signaling via
cardiac speciﬁc ablation of Raptor, the scaﬀolding protein
required for association of mTOR with its substrates p70 s6
kinase (S6K1) and eIF4E-binding protein (4E-BP), induces
impairment of adaptive hypertrophy and causes heart failure
in mice [50–54]. Given the fact that mTOR signaling is
required for adaptive cardiac hypertrophy, it is conceivable
that activation of mTORC1 in cardiac tissue in response to
excess nutrients, Ang II, and INS can be a compensatory
mechanism to help the heart cope with overnutrition-
related stresses such as hemodynamic overload. In this
paper, we describe regulation of overnutrition-related
cardiac mTORC1 signaling by inherent protective feedback
mechanisms that involve mTORC1-mediated activation of
Ang II type 2 receptor (AT2R) and changes in microRNA
proﬁles that, in turn, can potentially downregulate S6K1
expression.
Chronic alcohol consumption, in the context of overnu-
trition,isanadditionallysigniﬁcantriskfactorthatpromotes
cardiac pathology and dysfunction [55]. Alcoholism may be
the most common form of drug abuse. Moderate alcohol
consumption has been associated with a reduced risk of
CVD and improvement of INS resistance [56, 57]. How-
ever, chronic alcoholism (excessive and prolonged alcohol
consumption with >80g of ethanol a day for >10 years)
can result in alcoholic cardiomyopathy [55–60]. Chronic
alcohol treatment inhibits protein synthesis in cardiac mus-
cles and cause protein loss [58–60]. This alcohol eﬀect is
mediated by an inhibition of stimulatory phosphorylation
of mTOR and S6K1 in cardiac tissue and subsequent
downregulation of protein synthesis [58]. We posit that
alcohol-mediated inhibition of mTOR/S6K1 activation may
contribute to attenuation of an important compensatory
mechanism (mTORC1 signaling) that can promote adaptive
hypertrophy under conditions of overnutrition. Moreover,
chronic alcohol administration is shown to alter microRNA
proﬁles in other tissues. A close examination of these
alcohol-regulated microRNAs indicates that some of these
microRNAs are also expressed in cardiac tissue. In this paper
we explore the possible cardiac outcomes related to impaired
myocardial INS metabolic signaling that can occur when
alcohol-induced microRNA modulations are superimposed
on overnutrition-induced adaptive compensatory signaling
mechanisms in heart tissue.
2. Overnutrition-InducedActivation of
mTORC1 and mTOR↔AT2R Signaling Loop
inCardiacTissueandCardiomyocytes
TOR is a 289-kDa serine/threonine protein kinase that is
evolutionarily conserved from yeast to man (mTOR) and
a member of the phosphatidylinositol 3-kinase- (PI3-K-)
related kinase (PIKK) family. Signals that activate the
canonical PI3-K-protein kinase B (Akt) pathway (growth
factor receptors, Ang II, INS-mediated activation of IRS-
1/PI3-K-Akt pathway) result in mTOR stimulation. Akt acti-
vates mTOR by directly phosphorylating mTOR at Ser2448
[37–42]. Akt also promotes mTORC1 complex formation
indirectly since it phosphorylates proline-rich Akt substrate
of 40kDa (PRAS40), the negative regulator of Raptor, and
promotes dissociation of PRAS40 from mTORC1 so that
Raptor is free to associate with mTOR substrates S6K1 and
4E-BP. Additionally, phosphorylation of tuberous sclerosis
complex 2 (TSC2) by Akt results in inhibition of its GTPase
activity and thus promotes GTP loading on Rheb (Ras
homolog enriched in brain) and Rheb-mediated mTORC1
activation [61]. Amino acids also activate mTORC1 via
heterodimeric Rag GTPases that promote translocation of
mTORC1toamembrane-boundcompartmentthatcontains
the mTORC1 activator, Rheb [62]. Moreover, these diverse
mechanisms for activation of mTORC1 by amino acids and
INS act in a cooperative manner and provide a physiological
explanation for increased mTORC1 signaling in response to
overnutrition-related increases in nutrients and INS [63].
However, mTORC1 activation contributes to heart and
skeletal muscle INS resistance since mTOR substrate S6K1
is a serine (Ser)/threonine kinase that phosphorylates IRS-
1, a critical INS signaling/docking molecule, on speciﬁc Ser
residues. Excessive Ser phosphorylation of IRS-1 attenuates
IRS-1tyrosinephosphorylationandIRS-1-PI3-Kassociation
and subsequent INS metabolic signaling. In this context,
mTORC1 activation can induce INS resistance in cardiac
tissue. However, it is also conceivable that development of
INS resistance in conditions of overnutrition and hyper-
insulinemia is actually a compensatory mechanism that
may serve to protect cardiac cells from excessive signaling
generated by excess INS and nutrients.
Cardiac mTORC1 activation may play a signiﬁcant role
inincreasedproteinsynthesisrequiredforadaptivehypertro-
phy.Inthiscontext,activationofmTORC1leadstoincreased
translation and cell growth by two mechanisms: ﬁrst, phos-
phorylation of Thr389 of S6K1 by mTOR results in activation
of S6K1 and subsequent phosphorylation of ﬁve evolution-
arily conserved residues (Ser235, Ser236, Ser240, Ser244, and
Ser247) of ribosomal protein S6 (RPS6) that activates RPS6.
RPS6increasestranslationof5 TOPmRNAsandproteinsyn-
thesis. Second, mTOR phosphorylates 4E-BP on Thr37 and
Thr46 and relieves 4E-BP-mediated repression of translationExperimental Diabetes Research 3
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Figure 1: The mTORC1-mediated increase in AT2R expression can lead to AT2R-mediated inhibition of mTOR substrates and modulate
mTORC1 signaling.
initiation factor eIF4E and thus enhances translation [39, 42,
50, 64–66]. It should be noted that cardiac overexpression
of mTOR protects against cardiac dysfunction following LV
pressure overload. Conversely, ablation of cardiac raptor
results in impairment of adaptive cardiac hypertrophy and
causes heart failure in mice [54]. Interestingly, mTOR also
protectsheartfrompathologicalhypertrophyassociatedwith
inﬂammatory response [52, 54]. These observations imply a
delicately balanced mTORC1 function that helps the heart
cope with stress induced by exercise, pressure overload, and
inﬂammation.Ourrecentﬁndingssupportthenotionthatin
the setting of overnutrition-induced impairment of cardiac
INS metabolic signaling, mTORC1 signaling is carefully
controlled by protective feedback mechanisms.
The CRS rodent model Zucker Obese (ZO) rat is polyp-
hagic due to a mutation in the leptin receptor and serves
as a model of overnutrition-induced INS resistance and
diastolic heart failure with preserved ejection fraction [67–
69]. Importantly, this genetic model manifests biochemical
and functional cardiac abnormalities that are seen in obese
humans; however, the ZO rat does not progress to overt dia-
betes until late in life. We observed activation of mTORC1 in
the left ventricle of ZO rats; however, a concomitant increase
ingrowth-inhibitoryAngIIreceptorAT2Rwasalsoobserved
[2]. It is conceivable that the hyperinsulinemic status of ZO
rat may simultaneously promote mTORC1 activation since
INS activates mTORC1 and increases AT2R expression [38,
70–72]. What is paradoxical is that accumulating evidence
indicates that AT2R activation is cardioprotective [73–77].
AT2R inhibits cell growth and mediates the beneﬁcial eﬀects
of AT1R blockade and PPAR-γ activation, reduces ﬁbroblast
growth and myocardial hypertrophy, and mediates the
antihypertrophic and antiﬁbrotic eﬀects of AT1R blockade
[76–80]. Since AT2R activates phosphatases, it is conceiv-
able that AT2R expression in cardiac tissue in response
to overnutrition/hyperinsulinemia can regulate mTORC1
kinase and down-stream signaling. Such regulation could
play a signiﬁcant role in maintaining the delicate balance of
mTORC1 activation that promotes compensatory adaptive
cardiac hypertrophy to cope with increased hemodynamic
load associated with obesity. Our observation that Ang II-
andINS-mediatedactivationofmTORC1signalinginmouse
cardiomyocytes is, in part, responsible for increased AT2R
expression (that may, in turn, regulate mTORC1 signaling)
supports this notion. Rapamycin treatment elevates glucose
intolerance in obese sand rat. We observed that rapamycin-
induced inhibition of mTORC1 and siRNA-mediated inhi-
bition of S6K1 attenuated elevation of AT2R expression.
Thus, treatments that ablate mTORC1 and inhibit AT2R do
not seem to be cardioprotective in overnutrition conditions.
Conversely, AT2R agonism in ZO rats by a nine-day infusion
(200μg·kg−1·day−1) of Novokinin (Nov), an AT2R agonist,
reduced the increase in mTORC1 signaling and yet improved
myocardial performance. In brief, mTORC1 activation leads
t ot h ef o r m a t i o no fa nm T O R ↔AT2R signaling loop that
can serve as a protective feedback mechanism to balance
enhanced mTORC1 signaling in cardiac tissue in conditions
of overnutrition-induced INS resistance and RAS activation
(Figure 1).4 Experimental Diabetes Research
3. Regulation of S6K1 by microRNA in
CardiacTissue
The microRNAs (miRNA) have emerged as an important
group of translational regulators that target and regulate
60%ofthemammaliangenome[81–84].Recentstudieshave
shown that cardiac muscle-rich miRNAs or myomiRNAs
such as mir-208 (mir-208a, b) play crucial roles in CVD
[85–87]. The miRNAs are natural, single-stranded, small
RNA molecules that are not translated into proteins and yet
serve the pivotal function of regulating gene expression. It is
estimated that only 1% of the genomic transcripts in mam-
maliancellsencodemiRNA. Genes encoding formiRNAs are
transcribed from DNA to produce a primary transcript (pri-
miRNA). The pri-mRNA is then processed into a shorter
precursor miRNA (pre-miRNA), which undergoes further
processing to form a mature, single-stranded miRNA that
is 18 to 24 nucleotides long. A mature miRNA binds to its
mRNA target at their complementary sequences and down-
regulates gene expression by either inhibiting the mRNA
translation to proteins or inducing mRNA degradation.
Studies on experimental heart failure models have identiﬁed
severalmiRN Asasdiﬀerentiallyexpressed(foracompletelist
of miRNAs that are diﬀerentially expressed in heart-failure
modelspleaseseethereview[88]).Thusacumulativechange
in miRNA proﬁle accompanies heart failure-associated car-
diac pathology. In contrast, a detailed study by Naraba and
Iwai has suggested that microRNA proﬁles of heart and
kidney do not show signiﬁcant changes in salt-sensitive
hypertension [89]. These researchers constructed microRNA
libraries using the kidneys of Dahl salt-sensitive and Lewis
ratstakingnormalorhigh-saltdiets(4groups)andidentiﬁed
91 previously reported and 12 new microRNAs and then
compared their expression proﬁles in kidney and heart
ventricles. They concluded that the microRNA system is
unlikely to contribute to salt-sensitive hypertension in Dahl
salt-sensitive rats. It has also been reported that plasma levels
of some miRNAs (mir-1, mir-208, mir-133a, mir-423-5p,
mir-499) can be used as biomarkers for myocardial injury
[90–92]. The mir-143 has recently emerged as an obesity-
induced miRNA that inhibits INS-stimulated Akt activation
and impairs glucose metabolism [93].
Individual miRNAs can regulate several hundreds of
genes and conversely a given gene can be regulated by
multiple miRNAs. Knocking out the mTOR gene has shown
to be embryonically lethal, however, knocking out S6K1 gene
(RPS6KB1) seems to confer some beneﬁcial health aspects
to mice. Mice deﬁcient in S6K1, though they have a small
body size and reduced β-cell mass, are protected from INS
resistance in conditions of overnutrition [94]. We observed
thatinZOratcardiacLVtissue,totalS6K1proteinlevelswere
signiﬁcantly downregulated (Figure 2), and this prompted
us to analyze whether or not a change in miRNA proﬁle
that modulates S6K1 translation and mRNA stability plays
a role in reducing the protein levels of S6K1. To identify what
miRNAs bind rat S6K1 mRNA, we performed a RegRNA
analysis [95] of the 2287bp rat S6K1 mRNA. It was found
that298putativemiRNAscanbindratS6K1mRNA.Wehave
initiated miRNA proﬁling studies of Zucker lean (ZL) and
ZO cardiac tissues. The miRNA was isolated with mirVana
mirNA isolation kit (Ambion Inc.) from fresh frozen tissues
(n = 3 for each group), and was labeled with FlashTag Biotin
HSR RNA Labeling Kit. Aﬀymetrix miRNA GeneChip that
carries 46,228 probes comprising 7,815 probe sets, including
controls, was used for this study. The probes on this chip
are derived from the Sanger miRBase miRNA database v11
(April 15, 2008, http://microrna.sanger.ac.uk)[ 96]. Data an-
alysis was by miRNA QC tool and Signiﬁcance Analysis of
Microarrays (SAM) software (http://stat.stanford.edu/∼tibs/
SAM/). We compared the list of 298 miRNAs that can
potentially modulate S6K1 expression with the list of sta-
tistically signiﬁcant diﬀerentially expressed miRNAs in ZO
LV tissue compared to ZL LV tissue. This analysis showed
that only four of these S6K1-modulating miRNAs had a
very modest, but statistically signiﬁcant, increase in their
expression compared to that of the ZL control cardiac tissues
(Figure 2).
Three of these miRNAs, rno-let-7c, rno-mir-23a, and
rno-mir-26a,wereamongtheabundantlyexpressedmiRNAs
in ZO cardiac tissue. This was not surprising since these
miRNAs are shown to be expressed in heart and upregulated
in experimental models for heart failure [88]. In contrast,
rno-mir-200c was expressed modestly in ZO cardiac tissue.
The rno-mir-200c is located on chromosome 4 and inter-
estingly, QTLs associated with mir-200c include heart rate
QTL (Figure 3). The mir-200c has emerged as a cell growth
inhibitor and targets apoptosis inhibitor FAP-1 [97]. The
mir-200c also regulates stem cell factors, and it has been
proposed that targeting the ZEB1-miR-200 feedback loop
can lead to a promising treatment for fatal tumors, such
as pancreatic cancer [98]. Therefore, it is conceivable that
the modest mir-200c upregulation in cardiac tissue from an
overnutrition model reﬂects a compensatory mechanism to
delicately balance mTORC1 signaling and to control hyper-
trophy. While none of the S6K1 targeting miRNAs showed
robust increase in ZO cardiac tissue compared to that of ZL,
it is possible that a modest upregulation of multiple miR-
NAs that target diﬀerent regions of S6K1mRNA (Figure 2)
may achieve optimum regulation of S6K1 expression (by
either reducing translation or mRNA degradation) without
completely ablating S6K1 and inhibiting its beneﬁcial down-
stream eﬀects such as AT2R upregulation.
4. A Possible Molecular Explanationfor
Exacerbationof Cardiomyopathy by Chronic
Alcohol Consumption under Conditions
of Overnutrition
Although light to moderate alcohol consumption is cardio-
protective, regular heavy ethanol consumption results in a
form of dilated cardiomyopathy characterized by reduced
contractility, ventricular dilatation, cardiomyocyte apopto-
sis,andﬁbrosis,oftenprogressingtocardiacfailure[99–102].
The risk of alcoholic cardiomyopathy is greater in women
than men for any given life time amount of alcohol [103].
The “2008-2013 Action Plan” by World health Orga-
nization estimates that noncommunicable diseases (NCDs)Experimental Diabetes Research 5
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Figure 2: (a) Locations of miRNA binding sites on 2287bp S6K1 mRNA. Location of open reading frame (ORF) is marked. (b)
Representative autoradiogram showing S6K1 protein levels in ZO and ZL LV tissues. ∗P<0.05 for ZO versus ZL LV tissue. (c) % increase in
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Figure 3: Location of rno-mir-200c on the chromosome 4 of rat with associated QTLs and protein coding regions as shown in Ensemble
Rattus norvegicus version 63.34. rno-mir-200c is associated with Heart rate QTL 13.6 Experimental Diabetes Research
including CVDs, diabetes, cancers, and chronic respiratory
diseases, constitute 60% of mortality globally and can
be prevented by eliminating the shared risk factors that
include alcohol abuse [104]. Epidemiological studies show
either an inverted U-shape or a positive linear relationship
between alcohol consumption and INS sensitivity [105].
Chronic heavy alcohol consumption has been associated
with the development of INS-resistant syndrome [106,
107]. A recent study on patterns of alcoholic consumption
and Metabolic Syndrome has reported that “drinking in
excess of the dietary guidelines was associated with an
increased risk of impaired fasting glucose/diabetes mellitus,
hypertriglyceridemia, abdominal obesity, and high blood
pressure” [108].
Chronic ethanol ingestion in rats resulted in decreased
expression of GLUT4 accompanied by downregulation of
INS receptor-beta subunit, INS receptor substrate-1 (IRS-1)
in rat cardiac tissues [109]. Chronic ethanol feeding (12
weeks) to FVB mice resultedin glucose intolerance, impaired
cardiac glucose uptake, cardiac hypertrophy, and contrac-
tile dysfunction [110]. Ethanol feeding had no eﬀect on
either the expression of INS receptor β and IRS-1 with
or without INS stimulation in cardiomyocytes or basal
phosphorylated INS receptor (Tyr1146), basal tyrosine, and
Ser phosphorylated IRS-1 [110]. However, chronic alcohol
ingestion signiﬁcantly impaired INS-stimulated tyrosine
phosphorylation of INS receptor, IRS-1, and Akt, S6K1.
In alcohol dehydrogenase (ADH), transgenic mice ethanol-
induced decrease in tyrosine phosphorylation of IRS-1 was
further increased without aﬀecting the INS receptor. Alcohol
ingestion signiﬁcantly enhanced INS stimulated Ser phos-
phorylation of IRS-1, the eﬀe c to fw h i c hw a se x a g g e r a t e di n
ADHtransgenicmice[110].Incontrast,mitochondrialalde-
hyde dehydrogenase-2 (ALDH2) overexpression attenuated
alcohol-induceddecreaseintyrosinephosphorylationofINS
receptor and IRS-1. Moreover, increased Ser phosphoryla-
tion of IRS-1 and decreased phosphorylation of Akt caused
byalcoholingestionwerereversedbyALDH2overexpression
[111]. These results favor the role of ethanol metabolism and
acetaldehyde in alcohol-induced myocardial INS resistance
and myocardial dysfunction.
Recent studies have shown that chronic alcohol treat-
ment results in inhibition of mTORC1 signaling in cardiac
tissues [59], and this eﬀect of alcohol is involved in reduced
protein synthesis and cardiac muscle waste. Inhibition of
mTORC1 signaling by chronic alcohol consumption has also
been reported in cerebral cortex [112]. Interestingly, this
eﬀectofalcoholwasindependentofTSC2orAktphosphory-
lation status suggesting that other mechanisms are involved
in alcohol-mediated mTORC1 inhibition. The observation
that alcohol inhibits mTORC1 signaling in the heart is
particularly noteworthy since this eﬀect of alcohol opposes
overnutrition-mediated signaling in heart. As discussed in
the previous sections, mTORC1 signaling plays a pivotal
role in regulating cardiac health and pathology. Activation
of mTORC1 signaling in heart tissue and cardiomyocytes
underlies initiation of compensatory mechanisms such as
upregulation of the AT2R that has cardio-protective eﬀects.
A delicate balancing of mTORC1 signaling in cardiac tissues
under overnutrition conditions is mediated by mTOR↔
AT2R signaling loop and a moderate downregulation of total
S6K1 protein by changes in miRNA proﬁles. Therefore, it
is conceivable that alcohol-mediated inhibition of mTORC1
signaling may attenuate natural compensatory mechanisms
that help the heart to cope with overnutrition (Figure 4).
Another eﬀect of alcohol is its ability to downregulate
mir-200a [113, 114] as shown by studies involving Lieber-
DeCarli diet-induced alcoholic steatohepatitis mice models.
The mir-200 family microRNAs are shown to function
as inhibitors of growth in many cell types. Therefore,
downregulation of mir-200 family microRNAs by alcohol
can potentially increase growth and S6K1 protein levels.
Alcohol-mediated upregulation of the micoRNA mir-212 is
implicated in alcoholic liver disease [115]. Interestingly, mir-
212 has emerged as an activator of fetal gene program [116,
117].ChronicheartfailureischaracterizedbyLVremodeling
and activation of the fetal gene program. The mir-212 is
overexpressed in failing hearts. Additionally, transfection
of isolated adult rat cardiomyocytes with a set of fetal
miRNAs (miR-21, miR-129, and miR-212) induced cellular
hypertrophy and activation of a fetal gene program [117].
Since alcohol is shown to up-regulate mir-212 in other cell
types, it is conceivable that alcohol-mediated upregulation
of mir-212 can be one of the mechanisms by which alcohol
exacerbates cardiomyopathy.
Activation of RAS may contribute to progression of
alcoholiccardiomyopathy.Bingemodeethanolconsumption
in chronic alcohol abuse patients and heavy alcohol con-
sumption is associated with increased plasma angiotensin
levels [118]. Studies on alcohol ingestion and cardiac injury
in dogs showed that activation of RAS was followed by
a progressive fall in LV contractility during six months
of alcohol ingestion [119]. Moreover, angiotensin receptor
blockerirbesartanpreventedthesealcohol-induceddecreases
in LV and myocyte contraction [119]. Recent animal studies
in which chronic alcohol consumption with superimposed
binge mode of ethanol administration has been associated
with upregulation of RAS in the heart [120]. However,
ethanol ingestion alone usually does not result in severe
cardiac injury seen in humans and robust activation of RAS
[118]. In this regard, gene polymorphism for angiotensin
converting enzyme (ACE) is associated with increased vul-
nerability to alcoholic cardiomyopathy [121].
One signaling cascade activated by ethanol and
angiotensin is activation of mitogen-activated protein
kinases (MAPKs) including ERK1/2. The activation of
RAS and cardiac injury caused by chronic ethanol were
associated with activation of ERK1/2 in cardiac tissues,
and both activation of RAS and activation of ERK1/2
were reduced by inhibition of ERK1/2 signaling through
administration of MEK inhibitor PD98059 [120]. In this
regard, it is interesting to note that ethanol potentiates
ERK1/2 activation induced by angiotensin in hepatocytes
[122]. Ang II inhibited INS-induced glucose uptake in
vascular smooth muscle cells in an ERK1/2-dependent
manner, and increased Ser307 phosphorylation of IRS-1
was also inhibited by MEK inhibitor PD98059 [123]. Ang II
causes INS resistance in cardiomyocytes which is sensitiveExperimental Diabetes Research 7
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to ERK1/2 inhibition [124]. In this regard, the role of
mir-212 is noteworthy. Mir-212 has been shown to be
upregulated by ethanol in intestinal cells [115]a n dA n gI I
in cardiac ﬁbroblasts, which is associated with activation
of ERK1/2 pathway [125]. Chronic ethanol ingestion also
caused increased cardiac phosphorylation of CREB [126].
The signiﬁcance of CREB phosphorylation emerges from a
study reporting regulation of mir-212 in a CREB-dependent
manner involving ERK1/2 activation [127]. Acetaldehyde
causes activation of MAPKs including ERK1/2 in fetal
human cardiac myocytes and ALDH2 transgene attenuated
acetaldehyde-induced activation of phosphorylation of
ERK1/2 and SAP/JNK [128]. Moreover, regulation of human
microRNA-generating complex by MAPK/ERK pathway has
also been reported [129]. These ﬁndings suggest possible
interactions between alcohol and angiotensin on MAPK
signaling and INS signaling through modulation of
microRNA pathway in alcoholic cardiomyopathy.
Collectively, chronic alcohol consumption superimposed
on overnutrition-mediated cardiac pathology can putatively
induce the following signaling mechanisms: (1) inhibition
of mTORC1 and attenuation of protective compensatory
mechanisms; (2) inhibition of INS metabolic signaling via
downregulation of INS receptor, IRS-1, GLUT4; (3) down-
regulation of growth inhibitory mir-200 family microRNAs
and (4) upregulation of mir-212 (Figure 4).
It is suggested that mTOR inhibits autophagy in
myocardium, and this inhibition of autophagy by mTOR
can result in accumulation of abnormal proteins that lead
to enhanced endoplasmic reticulum stress, apoptosis, and
cardiac dysfunction [130, 131]. Inhibition of mTOR by
Everolimus (Rapamycin) seems to accentuate autophagy
and improve cardiac function [130–132]. In this context, a
recent study that demonstrates alcohol-induced autophagy
in myocardium [133] is particularly noteworthy. This study
shows that chronic alcohol treatment-induced cardiac dys-
function is associated with attenuation of mTOR stimula-
tory phosphorylation and induction of autophagy in mice;
however, ALDH2 overexpressing mice were protected from
these eﬀects. Interestingly, ALDH2-mediated protection of
heart in this model of chronic alcoholism seems to be
mediated through Akt-mTOR-STAT3 (Signal Transducer
and Activator of Transcription 3) signaling [133]. These data
further support the notion that mTOR activation is cardio-
protective [133, 134]. They also highlight the need for a
cautious approach towards treatments involving ablation of
mTOR-signaling in heart since enhanced autophagy can also
deteriorate heart condition.
However, chronic alcohol intake also suppresses AMP
kinase (AMPK) phosphorylation in myocardium [133].
Accumulating evidence suggests that AMPK is involved in
GLUT4 translocation and glucose uptake [135–137]. Thus,
inhibiting AMPK activation is an additional mechanism
by which alcohol can dampen insulin metabolic signaling
(Figure 4). Indeed, it is reported that in rats subjected to
chronicalcoholconsumption,theexpressionofAMPKalpha,
and myocyte enhancer factor 2 (MEF2) is signiﬁcantly
reduced and this reduction is associated with GLUT4 decline
[138].8 Experimental Diabetes Research
5.Perspectives
In conditions of chronic alcohol intake and overnutrition,
the potential compensatory mechanisms activated during
overnutrition-related insulin resistance alone are overridden
by alcohol-induced detrimental signaling (Figure 4). More-
over, since both overnutrition and alcohol activate RAS,
and alcohol dampens insulin-signaling, insulin resistance
is further exacerbated in cardiac tissue (Figure 4). In such
conditions, upregulation of mir-212 by both alcohol and
Ang II can lead to activation of fetal gene program and
heart failure. Thus mir-212 can be a potential therapeutic
target to protect the heart in conditions of overnutrition
and chronic alcoholism. Recent advances in microRNA
therapeutics are directed to develop eﬀective strategies to
block inappropriate expression of individual miRNAS that
contribute to diseases [139–141]. In this context, the fact
that miRNAs target multiple, functionally related genes
(versus single genes), renders them powerful therapeutic
tools. Antisense oligomers are known to work successfully
in mammals [142–144]. A number of gene delivery systems
have been developed to micromanage miRNAs by expressing
such antisense oligonucleotides which include plasmids, and
vectors based on adenoviruses, retroviruses, and lentiviruses.
Cholesterol-conjugated antagomirs also provide an eﬀective
way to inhibit the activity of an miRNA. For example, the
mir-21 antagomir/eraser is shown to be eﬀective in alleviat-
ing cardiac ﬁbrosis and hypertrophy since it derepresses the
expression of mir-21target SPRY1 and increases myoﬁbrob-
last apoptosis [144–146]. Therapeutic delivery of miRNAs
canalsobeaverypowerfulstrategytoregulatemultiplegenes
at the same time. For example, therapeutic delivery of mir-
200c is shown to ameliorate renal tubulointerstitial ﬁbrosis
[147]. However, a better understanding of the factors that
regulate the rate and order of miRNA-mediated silencing of
gene expression, colocalization of mRNA and miRNA, and
miRNA turnover is crucial for optimizing the techniques for
micromanipulating miRNAs as therapeutic targets.
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